University of Paris-Saclay-ko ikertzaileekin lankidetzan egindako argitalpenak (10)

2023

  1. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

    The Lancet Oncology, Vol. 24, Núm. 8, pp. 925-935

  2. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆

    Annals of Oncology, Vol. 34, Núm. 1, pp. 10-32

  3. Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer

    ESMO Open, Vol. 8, Núm. 2

2019

  1. Phase I study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (atezolizumab) in advanced solid tumors

    Clinical Cancer Research, Vol. 25, Núm. 11, pp. 3220-3228

  2. Regorafenib dose escalations in the prospective, observational CORRELATE study in patients with metastatic colorectal cancer

    Annals of Oncology, Vol. 30, pp. iv119

  3. Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study

    European Journal of Cancer, Vol. 123, pp. 146-154

2017

  1. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

    European Journal of Cancer, Vol. 82, pp. 16-24

2016

  1. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

    Annals of Oncology, Vol. 27, Núm. 8, pp. 1386-1422

2014

  1. Unmet needs and challenges in gastric cancer: The way forward

    Cancer Treatment Reviews, Vol. 40, Núm. 6, pp. 692-700

2012

  1. Esmo consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

    Annals of Oncology, Vol. 23, Núm. 10, pp. 2479-2516